EURAZEO_REGISTRATION_DOCUMENT_2017

PRESENTATION OF THE GROUP Other Management Report information

CROSSING OF OWNERSHIP THRESHOLDS Pursuant to Article L. 233-6 of the French Commercial Code, the Executive Board's report submitted to the Shareholders' Meeting must disclose (1) any acquisition of an interest in a French company during the year, representing more than one-twentieth, one-tenth, one-fifth, one-third or one-half of the share capital of the company concerned, and (ii) the acquisition of any controlling interest in such a company. In 2017, Eurazeo formed the companies Legendre Holding 56 (renamed LH WS), Legendre Holding 57, Legendre Holding 58, Legendre Holding 59, Legendre Holding 60, Legendre Holding 61 (renamed LH GP) and Legendre Holding 62 (companies 100% held when incorporated). SUBSEQUENT EVENTS In January 2018, Eurazeo Croissance announced its acquisition of a • minority stake in ContentSquare, leader in web and mobile customer experience analytics in SaaS mode, as part of a $42 million fundraising carried out with Canaan and Highland Europe to pursue the company’s development in Europe and the U.S. On March 6, 2018, via its subsidiary Legendre Holding, Eurazeo • sold its remaining stake in Accor SA (“Accor”), i.e. 12,185,303 shares representing 4.20% of Accor’s capital, at €45.28 per share. The cash impact net of taxes, expenses and other liabilities relating to the transaction was €484 million for Eurazeo, which achieved a gross multiple of 2x its initial investment in May 2008, taking into account the sale of Edenred in March 2013. Following the transaction’s completion, Eurazeo ceases to hold shares in Accor directly or indirectly. On March 9, 2018, Eurazeo announced a strengthened governance • process to support its growth strategy. Virginie Morgon will succeed Patrick Sayer as Eurazeo’s CEO on March 19, 2018. In the context of this succession, Eurazeo has announced certain changes to its governing bodies.

On May 2, 2017, Eurazeo acquired CPK, in which it owns 90.14% of the share capital as of December 31, 2017, through its subsidiary LH CPK (67.9% direct interest as of December 31, 2017). Eurazeo PME, as the management company of the midcap investment funds Eurazeo PME IIIA and Eurazeo PME IIIB, performed the following acquisitions: Smile on May 30, 2017, in which Eurazeo PME Capital indirectly • holds 66.2%* of the share capital as of December 31, 2017; and In’Tech Medical on July 12, 2017, in which Eurazeo PME Capital • indirectly holds 54.7% (1) of the share capital as of December 31, 2017. The Executive Board remains responsible for the company’s overall governance, relations with its Board of Directors, its Supervisory Board and its shareholders, and the monitoring of its financial performance and external communications. In addition to the Chairwoman Virginie Morgon, the Board will comprise Mr. Philippe Audouin, Directeur Général Finances - CFO, Mr. Nicolas Huet, General Counsel, and Mr. Olivier Millet, Chairman of the Eurazeo PME Executive Board. Eurazeo will also expand the role of its Executive Committee and change its composition. The Executive Committee will be responsible for defining, implementing and monitoring the Company’s strategies. These include the diversification of our investment sectors and asset classes, international deployment, fundraising, the analysis of our market environment, and external growth operations. It will also oversee the operational performance of our companies, HR development, and our CSR policy, as well as innovation and digitalization projects. It will comprise members of the Executive Board as well as Mr. Marc Frappier, Managing Partner and Head of Eurazeo Capital, Mr. Renaud Haberkorn, Managing Partner and Head of Eurazeo Patrimoine, Mr. Frans Tieleman, Managing Partner and Head of Eurazeo Development, as well as Mrs. Caroline Hadrbolec, Chief Human Resources Officer.

OUTLOOK

In 2018, Eurazeo wishes to pursue the announced strategic projects under the leadership of Virginie Morgon. In the first half of 2018, Eurazeo plans to finalize its investments in Rhône and Idinvest, thus

Eurazeo Patrimoine plans to finalize the acquisition of the group of 11 C2S clinics, following the announcement in December 2017 that it has

entered into exclusive discussions with the vendor Bridgepoint. creating a Private Equity leader managing over €15 billion to drive the Eurazeo Capital’s development will be based on a new fundraising growth of businesses. In Europe and North America, we will pursue our operation. At the same time, we will analyze the opportunities of active investment policy for each of our activities: the three divisions selling some of our investments, in full or in part, as part of our asset of Idinvest (Venture Capital, Private Debt, Funds of Funds), Eurazeo rotation strategy. Finally, we will continue to develop the portfolio Capital (including Rhône), Eurazeo Patrimoine (including Rhône – companies by supporting them with their transformation: digital, CSR, WeWork), Eurazeo PME, Eurazeo Croissance and Eurazeo Brands. international growth and external growth.

Percentage of control. (1)

87

Eurazeo

2017 Registration document